Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Programmed Cell Death 1 Ligand 1(PDL1, PD-L1)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07141186
What this trial is testing

QL1706 in Patients With Recurrent and Metastatic Cervical Cancer Resistant to Prior PD-1/PD-L1 Antibody Therapy

Who this might be right for
Cervical CancerCervical Cancer MetastaticCervical Cancer Recurrent+2 more
Tianjin Medical University Cancer Institute and Hospital 50
Testing effectiveness (Phase 2)Study completedNCT02970981
What this trial is testing

Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma

Who this might be right for
Melanoma
NYU Langone Health 18
Testing effectiveness (Phase 2)UnknownNCT03544723
What this trial is testing

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Who this might be right for
Solid TumorLymphoma
MultiVir, Inc. 40
Early research (Phase 1)Study completedNCT02180061
What this trial is testing

Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041)

Who this might be right for
Melanoma
Merck Sharp & Dohme LLC 42
Large-scale testing (Phase 3)Study completedNCT03976375
What this trial is testing

Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

Who this might be right for
Metastatic Non-Small Cell Lung Cancer
Merck Sharp & Dohme LLC 422
Testing effectiveness (Phase 2)Active Not RecruitingNCT02525757
What this trial is testing

MPDL3280A With Chemoradiation for Lung Cancer

Who this might be right for
Lung CancerNon-Small Cell Lung Cancer
M.D. Anderson Cancer Center 52
Testing effectiveness (Phase 2)Study completedNCT03516981
What this trial is testing

Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)

Who this might be right for
Advanced Non-Small Cell Lung Cancer
Merck Sharp & Dohme LLC 245
Large-scale testing (Phase 3)Study completedNCT02256436
What this trial is testing

Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)

Who this might be right for
Urothelial Cancer
Merck Sharp & Dohme LLC 542
Testing effectiveness (Phase 2)Looking for participantsNCT06492759
What this trial is testing

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma
Emory University 29
Testing effectiveness (Phase 2)Study completedNCT04216953
What this trial is testing

MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma

Who this might be right for
Sarcoma,Soft Tissue
Centre Leon Berard 229
Large-scale testing (Phase 3)Study completedNCT02563002
What this trial is testing

Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)

Who this might be right for
Colorectal Carcinoma
Merck Sharp & Dohme LLC 307
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07561775
What this trial is testing

Adebrelimab Plus S-1 for Resected Cholangiocarcinoma

Who this might be right for
CholangiocarcinomaBiliary Tract Cancer
Xingjun Guo 40
Early research (Phase 1)Study completedNCT02821000
What this trial is testing

Safety and Efficacy Study of Pembrolizumab (MK-3475) in Chinese Participants With Locally Advanced or Metastatic Melanoma (MK-3475-151/KEYNOTE-151)

Who this might be right for
Melanoma
Merck Sharp & Dohme LLC 103
Large-scale testing (Phase 3)Active Not RecruitingNCT03833154
What this trial is testing

Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation

Who this might be right for
Carcinoma, Non-Small-Cell Lung
AstraZeneca 724
Large-scale testing (Phase 3)Looking for participantsNCT07459751
What this trial is testing

A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

Who this might be right for
Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
Shanghai Henlius Biotech 706
Testing effectiveness (Phase 2)Study completedNCT03989362
What this trial is testing

Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer

Who this might be right for
Cancer
Jounce Therapeutics, Inc. 61
Testing effectiveness (Phase 2)Looking for participantsNCT06532591
What this trial is testing

Neoadjuvant/Adjuvant Cadonilimab Plus Chemotherapy in Patients With Resectable PD-L1 Negative NSCLC

Who this might be right for
NSCLC
Sichuan Cancer Hospital and Research Institute 20
Testing effectiveness (Phase 2)UnknownNCT04530227
What this trial is testing

Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC

Who this might be right for
Early Stage Non-small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06016413
What this trial is testing

Adelbelimab Combination Chemotherapy in Neoadjuvant Therapy for Squamous Cell Carcinoma of the Head and Neck

Who this might be right for
Head and Neck Squamous Cell Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 30
Large-scale testing (Phase 3)Study completedNCT05298423
What this trial is testing

Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC 610
Next Page